1. Home
  2. SCLXW vs SAV Comparison

SCLXW vs SAV Comparison

Compare SCLXW & SAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

N/A

Current Price

$0.14

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

SAV

Saratoga Investment Corp 7.50% Notes due 2031

N/A

Current Price

$25.27

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
SCLXW
SAV
Founded
N/A
N/A
Country
United States
United States
Employees
30
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
SCLXW
SAV
Price
$0.14
$25.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.7K
32.0K
Earning Date
03-07-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$55,152,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.02
N/A
52 Week Low
$0.04
$25.05
52 Week High
$0.64
$25.55

Technical Indicators

Market Signals
Indicator
SCLXW
SAV
Relative Strength Index (RSI) 47.15 51.01
Support Level $0.08 N/A
Resistance Level $0.18 $25.35
Average True Range (ATR) 0.03 0.13
MACD -0.00 -0.02
Stochastic Oscillator 45.42 5.88

Price Performance

Historical Comparison
SCLXW
SAV

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: